权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Michigan-VUMC Biomarker Characterization Center

密歇根-VUMC 生物标志物表征中心

基本信息

批准号：
10684207
负责人：
ARUL M CHINNAIYAN
金额：
$ 93.64万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-15 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10684207
关键词：
Academic Medical Centers African American population Alternative Splicing Biological Assay Biological Markers Biopsy Cancer Patient Certification Clinical Clinical Treatment Collaborations Communities Development Diagnosis Diagnostic tests Disease ERG gene Early Detection Research Network Early Diagnosis Future Gene Fusion Generations Goals Guidelines Health Incidence Indolent Industry Laboratories Malignant Neoplasms Malignant neoplasm of prostate Metastatic Prostate Cancer Michigan Minority Enrollment Minority Groups Mission Mutation New York PSA screening Pathology Patients Performance Population Population Heterogeneity Populations at Risk Procedures Prostate Prostatic Diseases RNA Splicing Reproduction spores Research Research Design Research Personnel Running Sampling Screening for Prostate Cancer Specificity Standardization TMPRSS2 gene Testing Texas Therapeutic Intervention Time Transcript United States Universities Untranslated RNA Urine Validation Variant Virginia Work biomarker validation cancer biomarkers circular RNA clinically significant cohort commercialization curative treatments detection test early detection biomarkers health disparity improved industry partner insertion/deletion mutation medical schools men mortality multidisciplinary next generation novel novel diagnostics novel marker overtreatment personalized risk prediction prevent shared decision making specific biomarkers transcriptome sequencing transcriptomics urinary

项目摘要

Project Summary/Abstract This application proposes the formation of the Michigan-Vanderbilt University Medical Center (VUMC) EDRN Biomarker Characterization Center (BCC). This BCC represents a collaborative, multi-disciplinary team of academic (University of Michigan (U-M) and VUMC) and industry (LynxDx) partners focused on discovering, developing, and scaling clinical-grade assays for the early detection of aggressive prostate cancer. Through previous EDRN efforts, our team characterized multiple important prostate cancer biomarkers, most notably the TMPRSS2-ETS gene fusions. Through collaboration with an EDRN Clinical Validation Center (CVC; Dr. Sanda PI), we developed, validated, and clinically implemented MyProstateScore (MPS), an early detection test incorporating urine quantification of two prostate cancer-specific transcripts—the TMPRSS2:ERG gene fusion and the long non-coding RNA (lncRNA) PCA3. Introduced in our CLIA laboratory, MPS informs shared decision making after PSA testing based on individualized risk predictions of aggressive prostate cancer on biopsy. Here, pairing the cancer-specific components of the MPS test with recent discovery of high-grade cancer-specific biomarkers, we outline the development, optimization, and clinical validation of the next generation of diagnostic tests – capable of reliably, selectively detecting potentially lethal cancers that stand to benefit from early curative treatment. Our Biomarker Developmental Laboratory (BDL) will employ the experimental platform, MPS-SEQ, for capture RNA-seq analysis of urine samples to detect aggressive prostate cancer transcripts, lncRNAs, circular RNAs, fusion transcripts, mutations, indels, and splice variants. Our Biomarker Reference Laboratory (BRL) will in parallel develop a clinical grade urine assay, MPS-50, for the multiplex QPCR analysis of up to 50 amplicons. While the first 50 amplicons of MPS-50 have already been nominated, future improvements of the assay content and platform will be informed by work carried out in our BDL. To fuel these studies, our BCC has identified urine biospecimen cohorts collected under rigorous standard operating procedures in compliance with PRoBE criteria including the Michigan Prostate SPORE, Emory University, the Center for Prostate Disease Research, University of Texas San Antonio Health, Eastern Virginia Medical School, and VUMC/Meharry Medical College. The overall Aims of this BCC serve to develop, assess, and optimize MPS-SEQ and MPS-50 for identifying high-grade prostate cancer in diverse at-risk populations. Our BRL will also focus on standardizing clinically-validated biomarker assays for consistent and reliable use in accordance with CLIA/CAP guidelines at the U-M Center for Translational Pathology in order to facilitate network consortium studies and at LynxDx in order to scale, commercialize, and obtain FDA approvals. As recognized by the EDRN, novel biomarkers specific for aggressive prostate cancer are urgently needed. Importantly, our mission and efforts extend beyond our BCC and prostate cancer, as we actively participate in the EDRN biomarker community and support continued collaborative efforts with other BCCs and CVCs to advance the overall EDRN mission.

项目总结/摘要本申请提出了组建里根-范德比尔特大学医学中心（VUMC）EDRN的建议生物标志物表征中心（BCC）。这个BCC代表了一个协作的多学科团队，学术（密歇根大学（U-M）和VUMC）和行业（LynxDx）合作伙伴专注于发现，开发和扩展临床级检测方法，用于早期检测侵袭性前列腺癌。通过在EDRN之前的工作中，我们的团队描述了多种重要的前列腺癌生物标志物，最值得注意的是 TMPRSS 2-ETS基因融合体。通过与EDRN临床验证中心（CVC; Dr. Sanda）合作， PI），我们开发，验证，并在临床上实施MyProstateScore（MPS），一种早期检测测试结合两种前列腺癌特异性转录物的尿液定量-TMPRSS 2：ERG基因融合和长链非编码RNA（lncRNA）PCA 3。在我们的CLIA实验室推出，MPS告知共享决策 PSA检测后，根据活检的侵袭性前列腺癌的个体化风险预测。在这里，将MPS测试的癌症特异性成分与最近发现的高级别癌症特异性成分进行配对，生物标志物，我们概述了下一代诊断的发展，优化和临床验证测试-能够可靠地，选择性地检测可能致命的癌症，这些癌症可以从早期治疗中受益治疗我们的生物标志物开发实验室（BDL）将采用实验平台MPS-SEQ，用于尿液样品的捕获RNA-seq分析以检测侵袭性前列腺癌转录物，lncRNA，环状RNA、融合转录物、突变、插入缺失和剪接变体。我们的生物标志物参考实验室 (BRL)将同时开发一种临床级尿液检测试剂MPS-50，用于多达50 扩增子。虽然MPS-50的前50个扩增子已经被提名，但对MPS-50的未来改进仍然是可行的。检测内容和平台将通过我们的BDL中进行的工作进行通知。为了推动这些研究，我们的BCC已经按照严格的标准操作规程采集的已确定尿液生物标本队列， PRoBE标准包括密歇根州前列腺孢子，埃默里大学，前列腺疾病中心研究，德克萨斯大学圣安东尼奥健康，东弗吉尼亚医学院，和VUMC/Meharry 医学院该BCC的总体目标是开发、评估和优化MPS-SEQ和MPS-50 用于在不同的高危人群中识别高级别前列腺癌。我们的BRL还将专注于标准化临床验证的生物标志物检测，可根据CLIA/CAP指南一致可靠地使用，密歇根大学转化病理学中心，以促进网络联盟的研究和LynxDx在以扩大规模，商业化，并获得FDA的批准。正如EDRN所认识到的，新的生物标志物特异性治疗侵袭性前列腺癌重要的是，我们的使命和努力不仅限于BCC 和前列腺癌，因为我们积极参与EDRN生物标志物社区，并继续支持与其他BCC和CVC合作，推进EDRN的整体使命。